EMJ GOLD

Filter Advertise With Us

Ultragenyx sets $3.95m list price for fatal rare disease therapy

Ultragenyx has priced Fayuvi at $3.95m after FDA approval of the first treatment for Sanfilippo syndrome Type A.

Ultragenyx sets $3.95m list price for fatal rare disease therapy

Ultragenyx has priced Fayuvi at $3.95m after FDA approval of the first treatment for Sanfilippo syndrome Type A.

Woman holding pink ribbon on light background, closeup. Breast cancer awareness concept

NICE approves breast cancer drug after initial refusal

Enhertu has been recommended by NICE for NHS use in England, following an initial rejection due to cost in 2024.

Foil blister packs of pills piled on top of each other, each with different sizes, colours and shapes of pills and oral treatments in them.

Novo signs $1.4bn deal with Orbis to create new oral treatments

Novo and Orbis Medicines join forces to develop new oral treatments for cardiometabolic diseases.

Abbvie

AbbVie tees up brain health campaign with PGA TOUR

AbbVie partners with the PGA TOUR on Birdies for Brain Health, turning golf performance into support for patient organisations.

Closeup of the Novo Nordisk sign outside its office in Fremont, California. Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd

Novo Nordisk rebrands to the single name 'Novo'

The change to ‘Novo’ follows two years of share-price declines, a change of leadership and falling market share.

Takeda R&D head Andy Plump to retire after a decade

Andy Plump, the research and development chief who overhauled Takeda’s pipeline over more than a decade, will retire in June 2027.

Lungs shape made from yellow paper on a palm old woman on a blue background

AZ's COPD drug cuts flare-ups in two phase 3 trials

AstraZeneca’s experimental COPD drug has significantly reduced flare-ups in two late-stage trials, making FDA approval in 2027 now possible.

Woman-with-headache-and-stomach-pain-lying-on-a-couch-at-home

AbbVie drug meets phase 3 goal in menstrual migraine

AbbVie’s atogepant has met the primary endpoint of its phase 3 trial, which tested the drug as a preventive treatment for menstrual migraine.

Loading posts...

1 2 3 … 61 Next »